MA33455B1 - Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux - Google Patents

Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux

Info

Publication number
MA33455B1
MA33455B1 MA34566A MA34566A MA33455B1 MA 33455 B1 MA33455 B1 MA 33455B1 MA 34566 A MA34566 A MA 34566A MA 34566 A MA34566 A MA 34566A MA 33455 B1 MA33455 B1 MA 33455B1
Authority
MA
Morocco
Prior art keywords
treatment
otamixaban
patients
myocardial infarcts
elevation
Prior art date
Application number
MA34566A
Other languages
Arabic (ar)
English (en)
Inventor
Jens Stechl
Angèle Moryusef
Christophe Gaudin
Pascale Ythier-Moury
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA33455B1 publication Critical patent/MA33455B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A PRÉSENTE INVENTION CONCERNE L'UTILISATION D'ESTER MÉTHYLIQUE D'ACIDE (2R,3R)-2-(3-CARBAMIMIDOYL-BENZYL)-3-[4-(1-OXY-PYRIDIN-4-YL) BENZOYLAMINO]-BUTYRIQUE, OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN VUE DE LA PRÉPARATION D'UN MÉDICAMENT UTILISABLE EN CAS D'INFARCTUS DU MYOCARDE SANS ÉLÉVATION DU SEGMENT ST, LEDIT TRAITEMENT COMPRENANT L'ADMINISTRATION D'UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE D'ESTER MÉTHYLIQUE D'ACIDE (2R,3R)-2-(3-CARBAMIMIDOYL-BENZYL)-3-[4-(1-OXY-PYRIDIN-4-YL) BENZOYLAMINO]-BUTYRIQUE, OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, À UN PATIENT HUMAIN, ÂGÉ ET/OU SOUFFRANT D'INSUFFISANCE RÉNALE ET/OU DE FAIBLE POIDS.
MA34566A 2009-07-29 2010-07-22 Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux MA33455B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
EP10305192 2010-02-26
PCT/EP2010/060615 WO2011012527A1 (fr) 2009-07-29 2010-07-22 Otamixaban servant au traitement de patients âgés et insuffisants rénaux, victimes d'un infarctus du myocarde sans élévation du segment st

Publications (1)

Publication Number Publication Date
MA33455B1 true MA33455B1 (fr) 2012-07-03

Family

ID=42542846

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34566A MA33455B1 (fr) 2009-07-29 2010-07-22 Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux

Country Status (25)

Country Link
US (1) US9492437B2 (fr)
EP (1) EP2459193A1 (fr)
JP (1) JP2013500298A (fr)
KR (1) KR20120038982A (fr)
CN (1) CN102470128A (fr)
AR (1) AR077427A1 (fr)
AU (1) AU2010277725B2 (fr)
BR (1) BR112012001900A2 (fr)
CA (1) CA2766533A1 (fr)
CL (1) CL2012000196A1 (fr)
CO (1) CO6491041A2 (fr)
CR (1) CR20110674A (fr)
DO (1) DOP2012000012A (fr)
EC (1) ECSP12011627A (fr)
IL (1) IL217612A (fr)
MA (1) MA33455B1 (fr)
MX (1) MX2012000457A (fr)
NI (1) NI201200008A (fr)
NZ (1) NZ597957A (fr)
PE (1) PE20121401A1 (fr)
RU (1) RU2542455C2 (fr)
SG (1) SG177772A1 (fr)
TW (1) TWI463982B (fr)
UY (1) UY32807A (fr)
WO (1) WO2011012527A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5993933B2 (ja) * 2011-03-29 2016-09-14 サノフイ 安定性を改善したオタミキサバン製剤
TWI551289B (zh) * 2011-03-29 2016-10-01 賽諾菲公司 具有改良之安定性之奧米沙班調配物
RU2597423C2 (ru) * 2011-03-29 2016-09-10 Санофи Бензойнокислая соль отамиксабана
AU2013310973A1 (en) * 2012-08-31 2015-03-12 Sanofi Otamixaban for use in the treatment of non-ST elevation acute coronary syndrome in patients planned to undergo coronary artery bypass grafting

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723338B2 (en) * 1996-01-02 2000-08-24 Aventis Pharmaceuticals Inc. Substituted n-{(aminoiminomethyl or aminomethyl)phenyl}propyl amides
RU2225617C1 (ru) * 2002-12-16 2004-03-10 Научно-исследовательский институт кардиологии Томского научного центра СО РАМН Способ определения дифференцированного назначения гепаринов больным с острым коронарным синдромом без подъема сегмента st

Also Published As

Publication number Publication date
RU2012107483A (ru) 2013-09-10
CR20110674A (es) 2012-04-17
IL217612A (en) 2014-08-31
EP2459193A1 (fr) 2012-06-06
ECSP12011627A (es) 2012-02-29
US20120238605A1 (en) 2012-09-20
NI201200008A (es) 2012-05-29
JP2013500298A (ja) 2013-01-07
US9492437B2 (en) 2016-11-15
AU2010277725A1 (en) 2012-02-16
CL2012000196A1 (es) 2012-10-05
MX2012000457A (es) 2012-01-27
RU2542455C2 (ru) 2015-02-20
SG177772A1 (en) 2012-03-29
PE20121401A1 (es) 2012-10-25
AR077427A1 (es) 2011-08-24
TWI463982B (zh) 2014-12-11
CA2766533A1 (fr) 2011-02-03
CN102470128A (zh) 2012-05-23
BR112012001900A2 (pt) 2016-03-15
WO2011012527A1 (fr) 2011-02-03
DOP2012000012A (es) 2012-02-15
KR20120038982A (ko) 2012-04-24
AU2010277725B2 (en) 2016-08-18
UY32807A (es) 2011-02-28
CO6491041A2 (es) 2012-07-31
TW201119655A (en) 2011-06-16
NZ597957A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
MA30514B1 (fr) Nouveaux composes.
MA33374B1 (fr) Composition de surfactant reconstitué améliorée contenant des analogues de la protéine b du surfactant (sp-b) et de la protéine c du surfactant (sp-c)
MA38576A1 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA41496B1 (fr) Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA34002B1 (fr) Thérapie antivirale
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
EP4609912A3 (fr) Nouvelle utilisation d'une combinaison de sacubitril et de valsartan
MA35716B1 (fr) Formulations pharmaceutiques
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA33455B1 (fr) Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux
MA38425B1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
JP2015522077A5 (fr)
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA32299B1 (fr) Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
MA34130B1 (fr) Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation